Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Catcha Investment Corp CHAA | CITADEL ADVISORS LLC | 6,410 0.300% | -2,198,479 (-99.71%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Project Energy Reimagined Acquisition Corp. PEGR | CITADEL ADVISORS LLC | 172,489 1.000% | -2,043,562 (-92.22%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Spruce Biosciences, Inc. SPRB | CITADEL ADVISORS LLC | 108,240 0.300% | -1,639,151 (-93.81%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Ventyx Biosciences, Inc. VTYX | CITADEL ADVISORS LLC | 4,279,553 7.300% | 490,758 (+12.95%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Vera Therapeutics, Inc. VERA | CITADEL ADVISORS LLC | 43,447 0.100% | -1,948,106 (-97.82%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL | CITADEL ADVISORS LLC | 2,161,902 6.000% | -2,014 (-0.09%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Lexeo Therapeutics, Inc. Common Stock LXEO | CITADEL ADVISORS LLC | 2,084,267 7.800% | -8,221 (-0.39%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX | CITADEL ADVISORS LLC | 1,556,842 5.200% | 219,849 (+16.44%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL | CITADEL ADVISORS LLC | 3,738,482 5.300% | -101,347 (-2.64%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | VYNE Therapeutics Inc. VYNE | CITADEL ADVISORS LLC | 1,181,144 8.500% | -23 (-0.00%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Korro Bio, Inc. KRRO | CITADEL ADVISORS LLC | 529,251 6.600% | -16,967 (-3.11%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Aura Biosciences, Inc. AURA | CITADEL ADVISORS LLC | 3,631,494 7.400% | 894,441 (+32.68%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Bolt Biotherapeutics, Inc. BOLT | CITADEL ADVISORS LLC | 2,458,958 6.500% | -293,237 (-10.65%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Dyne Therapeutics, Inc. DYN | CITADEL ADVISORS LLC | 3,072,587 5.000% | 91,263 (+3.06%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Ikena Oncology, Inc. IKNA | CITADEL ADVISORS LLC | 178,177 0.400% | -1,976,957 (-91.73%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Immuneering Corporation IMRX | CITADEL ADVISORS LLC | 2,078,092 7.100% | -63,405 (-2.96%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | MoonLake Immunotherapeutics MLTX | CITADEL ADVISORS LLC | 2,034,260 3.400% | -851,832 (-29.52%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Acrivon Therapeutics, Inc. Common Stock ACRV | CITADEL ADVISORS LLC | 1,649,664 7.400% | 15,515 (+0.95%) | Filing History |
| 2024-02-14 4:57 pm Sale | 2023-12-31 | 13G | Northern Star Investment Corp. II NSTB | CITADEL ADVISORS LLC | 806 0.000% | -50,128 (-98.42%) | Filing History |
| 2024-02-14 4:57 pm Purchase | 2023-12-31 | 13G | Tourmaline Bio, Inc. TRML | CITADEL ADVISORS LLC | 2,265 0.000% | 2,265 (New Position) | Filing History |